FDA Action Alert: Merck, Agios and AMAG Pharma
FDA Action Alert: Merck, Agios and AMAG Pharma
Απεβίωσε ο Γιάννης Βλόντζος
Απεβίωσε ο Γιάννης Βλόντζος
Καινοτόμος θεραπεία για την πολλαπλή σκλήρυνση
Καινοτόμος θεραπεία για την πολλαπλή σκλήρυνση
Asco 2019 event analyser – low-key meeting belies some huge stock moves
Asco 2019 event analyser – low-key meeting belies some huge stock moves
Move aside, Humira. Merck’s Keytruda will capture industry’s top sales spot in 2024: report
Move aside, Humira. Merck’s Keytruda will capture industry’s top sales spot in 2024: report
All the ASCO skinny: Lynparza’s pancreatic win, Amgen’s KRAS spotlight, Merck’s history-busting and more
All the ASCO skinny: Lynparza’s pancreatic win, Amgen’s KRAS spotlight, Merck’s history-busting and more
AstraZeneca, Merck make case for PARP’s place in pancreatic cancer
AstraZeneca, Merck make case for PARP’s place in pancreatic cancer
15 new cancer drugs debuted in 2018—along with one big leap in drug spending
15 new cancer drugs debuted in 2018—along with one big leap in drug spending
Time to restock big pharma’s leaking pipeline
Time to restock big pharma’s leaking pipeline
5 novel immuno-oncology targets to know before ASCO
5 novel immuno-oncology targets to know before ASCO
Merck’s powerhouse Keytruda whiffs breast cancer trial, delaying hopes for new use
Merck’s powerhouse Keytruda whiffs breast cancer trial, delaying hopes for new use
Merck’s Keytruda Fails Triple-Negative Breast Cancer Trial
Merck’s Keytruda Fails Triple-Negative Breast Cancer Trial
Merck KGaA and Pfizer Snag FDA Approval for RCC Drug
Merck KGaA and Pfizer Snag FDA Approval for RCC Drug
Pharma, late to digital game, rushes to catch up
Pharma, late to digital game, rushes to catch up
FDA approved the first drug to prevent migraines. Here’s the story of its discovery—and its limitations
FDA approved the first drug to prevent migraines. Here’s the story of its discovery—and its limitations
Bristol-Myers’ Opdivo fails brain tumor test again, this time in new patients
Bristol-Myers’ Opdivo fails brain tumor test again, this time in new patients
